New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back
Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem in nearly 50% of patients with heart failure. Therefore, research on new strategies for its diagnosis and management has become imperative in recent years. Few drugs have successfully improved clinical outcomes...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/1/70 |
| _version_ | 1797445747596066816 |
|---|---|
| author | Alfredo Parra-Lucares Esteban Romero-Hernández Eduardo Villa Sebastián Weitz-Muñoz Geovana Vizcarra Martín Reyes Diego Vergara Sergio Bustamante Marcelo Llancaqueo Luis Toro |
| author_facet | Alfredo Parra-Lucares Esteban Romero-Hernández Eduardo Villa Sebastián Weitz-Muñoz Geovana Vizcarra Martín Reyes Diego Vergara Sergio Bustamante Marcelo Llancaqueo Luis Toro |
| author_sort | Alfredo Parra-Lucares |
| collection | DOAJ |
| description | Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem in nearly 50% of patients with heart failure. Therefore, research on new strategies for its diagnosis and management has become imperative in recent years. Few drugs have successfully improved clinical outcomes in this population. Therefore, numerous attempts are being made to find new pharmacological interventions that target the main mechanisms responsible for this disease. In recent years, pathological mechanisms such as cardiac fibrosis and inflammation, alterations in calcium handling, NO pathway disturbance, and neurohumoral or mechanic impairment have been evaluated as new pharmacological targets showing promising results in preliminary studies. This review aims to analyze the new strategies and mechanical devices, along with their initial results in pre-clinical and different phases of ongoing clinical trials for HFpEF patients. Understanding new mechanisms to generate interventions will allow us to create methods to prevent the adverse outcomes of this silent pandemic. |
| first_indexed | 2024-03-09T13:30:17Z |
| format | Article |
| id | doaj.art-891af4679849472aad2ed91764a17cf8 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T13:30:17Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-891af4679849472aad2ed91764a17cf82023-11-30T21:19:01ZengMDPI AGBiomedicines2227-90592022-12-011117010.3390/biomedicines11010070New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and BackAlfredo Parra-Lucares0Esteban Romero-Hernández1Eduardo Villa2Sebastián Weitz-Muñoz3Geovana Vizcarra4Martín Reyes5Diego Vergara6Sergio Bustamante7Marcelo Llancaqueo8Luis Toro9Critical Care Unit, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileMD PhD Program, Faculty of Medicine, Universidad de Chile, Santiago 8380420, ChileSchool of Medicine, Faculty of Medicine, Universidad de Chile, Santiago 8380420, ChileDivision of Internal Medicine, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileDivision of Internal Medicine, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileSchool of Medicine, Faculty of Medicine, Universidad de Chile, Santiago 8380420, ChileSchool of Medicine, Faculty of Medicine, Universidad de Chile, Santiago 8380420, ChileCoronary Care Unit, Cardiovascular Department, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileCoronary Care Unit, Cardiovascular Department, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileDivision of Nephrology, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago 8380420, ChileHeart failure with preserved ejection fraction (HFpEF) is a growing public health problem in nearly 50% of patients with heart failure. Therefore, research on new strategies for its diagnosis and management has become imperative in recent years. Few drugs have successfully improved clinical outcomes in this population. Therefore, numerous attempts are being made to find new pharmacological interventions that target the main mechanisms responsible for this disease. In recent years, pathological mechanisms such as cardiac fibrosis and inflammation, alterations in calcium handling, NO pathway disturbance, and neurohumoral or mechanic impairment have been evaluated as new pharmacological targets showing promising results in preliminary studies. This review aims to analyze the new strategies and mechanical devices, along with their initial results in pre-clinical and different phases of ongoing clinical trials for HFpEF patients. Understanding new mechanisms to generate interventions will allow us to create methods to prevent the adverse outcomes of this silent pandemic.https://www.mdpi.com/2227-9059/11/1/70heart failurepreserved ejection fractioncardiologytherapeuticstranslational medicine |
| spellingShingle | Alfredo Parra-Lucares Esteban Romero-Hernández Eduardo Villa Sebastián Weitz-Muñoz Geovana Vizcarra Martín Reyes Diego Vergara Sergio Bustamante Marcelo Llancaqueo Luis Toro New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back Biomedicines heart failure preserved ejection fraction cardiology therapeutics translational medicine |
| title | New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back |
| title_full | New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back |
| title_fullStr | New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back |
| title_full_unstemmed | New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back |
| title_short | New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back |
| title_sort | new opportunities in heart failure with preserved ejection fraction from bench to bedside and back |
| topic | heart failure preserved ejection fraction cardiology therapeutics translational medicine |
| url | https://www.mdpi.com/2227-9059/11/1/70 |
| work_keys_str_mv | AT alfredoparralucares newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT estebanromerohernandez newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT eduardovilla newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT sebastianweitzmunoz newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT geovanavizcarra newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT martinreyes newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT diegovergara newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT sergiobustamante newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT marcelollancaqueo newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback AT luistoro newopportunitiesinheartfailurewithpreservedejectionfractionfrombenchtobedsideandback |